222 related articles for article (PubMed ID: 28489748)
1. P16 protein expression as a useful predictive biomarker for neoadjuvant chemotherapy response in patients with high-grade osteosarcoma: A systematic meta-analysis under guideline of PRISMA.
Tang Y; Yang C; Guo Z; Fu Y; Yu X; Liu B; Zhou H; Wang J; Li W; Pang Q
Medicine (Baltimore); 2017 May; 96(19):e6714. PubMed ID: 28489748
[TBL] [Abstract][Full Text] [Related]
2. P16 expression predicts necrotic response among patients with osteosarcoma receiving neoadjuvant chemotherapy.
Borys D; Canter RJ; Hoch B; Martinez SR; Tamurian RM; Murphy B; Bishop JW; Horvai A
Hum Pathol; 2012 Nov; 43(11):1948-54. PubMed ID: 22578565
[TBL] [Abstract][Full Text] [Related]
3. p16 expression as a prognostic and predictive marker in high-grade localized osteosarcoma of the extremities: an analysis of 357 cases.
Righi A; Gambarotti M; Sbaraglia M; Sisto A; Ferrari S; Dei Tos AP; Picci P
Hum Pathol; 2016 Dec; 58():15-23. PubMed ID: 27544803
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
[TBL] [Abstract][Full Text] [Related]
5. p16 expression predicts neoadjuvant tumor necrosis in osteosarcomas: reappraisal with a larger series using whole sections.
Kosemehmetoglu K; Ardic F; Karslioglu Y; Kandemir O; Ozcan A
Hum Pathol; 2016 Apr; 50():170-5. PubMed ID: 26997452
[TBL] [Abstract][Full Text] [Related]
6. Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy.
Hattinger CM; Michelacci F; Sella F; Magagnoli G; Benini S; Gambarotti M; Palmerini E; Picci P; Serra M; Ferrari S
Histopathology; 2015 Sep; 67(3):338-47. PubMed ID: 25600168
[TBL] [Abstract][Full Text] [Related]
7. Cell Cycle Checkpoints p16 and p21-Strong Predictors of Clinicopathologic Outcomes in High-Grade Osteosarcoma.
Nasri E; Torrence DE; Vasilopoulos T; Knapik JA; Lagmay JP; Reith JD; Gibbs CP
Cancer J; 2024 May-Jun 01; 30(3):133-139. PubMed ID: 38753746
[TBL] [Abstract][Full Text] [Related]
8. pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma.
Thanapprapasr K; Nartthanarung A; Thanapprapasr D; Jinawath A
PLoS One; 2017; 12(8):e0182989. PubMed ID: 28846700
[TBL] [Abstract][Full Text] [Related]
9. Location of residual viable tumor cells after neoadjuvant chemotherapy: A new concept with high prognostic performance in osteosarcoma.
Kim SH; Shin KH; Moon SH; Kong Y; Suh JS; Yang WI
J Surg Oncol; 2017 May; 115(6):752-759. PubMed ID: 28403564
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of clinical significance of p53 protein expression in patients with osteosarcoma.
Wu J; Guo A; Li Q; Wang D
Future Oncol; 2017 Sep; 13(21):1883-1891. PubMed ID: 28766969
[TBL] [Abstract][Full Text] [Related]
11. p16 protein expression and correlation with clinical and pathological features in osteosarcoma of the jaws: Experience of 37 cases.
Asioli S; Righi A; Rucci P; Tarsitano A; Marchetti C; Bacchini P; Balbi T; Bertoni F; Foschini MP
Head Neck; 2017 Sep; 39(9):1825-1831. PubMed ID: 28560748
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Chemotherapy Followed by Delayed Surgery: Is it Necessary for All Patients With Nonmetastatic High-Grade Pelvic Osteosarcoma?
Xu J; Xie L; Guo W
Clin Orthop Relat Res; 2018 Nov; 476(11):2177-2186. PubMed ID: 29912746
[TBL] [Abstract][Full Text] [Related]
13. Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?
Yu W; Tang L; Lin F; Yao Y; Shen Z
Med Oncol; 2015 Jan; 32(1):307. PubMed ID: 25432694
[TBL] [Abstract][Full Text] [Related]
14. Correlation between Prognostic Factors and the Histopathological Response to Neoadjuvant Chemotherapy in Osteosarcoma: A Retrospective Study.
Prabowo Y; Setiawan I; Kamal AF; Kodrat E; Labib Zufar ML
Int J Surg Oncol; 2021; 2021():8843325. PubMed ID: 33996154
[TBL] [Abstract][Full Text] [Related]
15. P16INK4a overexpression and survival in osteosarcoma patients: a meta analysis.
Bu J; Li H; Liu LH; Ouyang YR; Guo HB; Li XY; Xiao T
Int J Clin Exp Pathol; 2014; 7(9):6091-6. PubMed ID: 25337256
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis.
Rossi B; Schinzari G; Maccauro G; Scaramuzzo L; Signorelli D; Rosa MA; Fabbriciani C; Carlo B
BMC Musculoskelet Disord; 2010 Feb; 11():34. PubMed ID: 20158913
[TBL] [Abstract][Full Text] [Related]
17. Livin and Bcl-2 expression in high-grade osteosarcoma.
Nedelcu T; Kubista B; Koller A; Sulzbacher I; Mosberger I; Arrich F; Trieb K; Kotz R; Toma CD
J Cancer Res Clin Oncol; 2008 Feb; 134(2):237-44. PubMed ID: 17632732
[TBL] [Abstract][Full Text] [Related]
18. The β5/focal adhesion kinase/glycogen synthase kinase 3β integrin pathway in high-grade osteosarcoma: a protein expression profile predictive of response to neoadjuvant chemotherapy.
Le Guellec S; Moyal EC; Filleron T; Delisle MB; Chevreau C; Rubie H; Castex MP; de Gauzy JS; Bonnevialle P; Gomez-Brouchet A
Hum Pathol; 2013 Oct; 44(10):2149-58. PubMed ID: 23845472
[TBL] [Abstract][Full Text] [Related]
19. Prognostic role of methylated GSTP1, p16, ESR1 and PITX2 in patients with breast cancer: A systematic meta-analysis under the guideline of PRISMA.
Sheng X; Guo Y; Lu Y
Medicine (Baltimore); 2017 Jul; 96(28):e7476. PubMed ID: 28700487
[TBL] [Abstract][Full Text] [Related]
20. T2-weighted MRI radiomics in high-grade intramedullary osteosarcoma: predictive accuracy in assessing histologic response to chemotherapy, overall survival, and disease-free survival.
White LM; Atinga A; Naraghi AM; Lajkosz K; Wunder JS; Ferguson P; Tsoi K; Griffin A; Haider M
Skeletal Radiol; 2023 Mar; 52(3):553-564. PubMed ID: 35778618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
